NCCN Recommendations for Gastric Cancer Chemotherapy

1. Classification of Chemotherapeutic Agents

• The NCCN classifies agents for gastric cancer into fluoropyrimidines, platinums, anthracyclines, taxanes, topoisomerase‑I inhibitors, and targeted/biologic therapies. [@1]

2. Core Cytotoxic Drugs

Fluoropyrimidines

• 5‑Fluorouracil (5‑FU) is the most active cytotoxic drug and forms the backbone of most combination regimens for gastric cancer. [@2]
• Capecitabine, an oral pro‑drug of 5‑FU, eliminates the need for a central venous line and has demonstrated non‑inferiority to 5‑FU in advanced disease. [@3]
• S‑1 (oral tegafur + gimeracil + oteracil) is widely used in Asian populations; adjuvant therapy with S‑1 yields a 5‑year overall survival of ≈ 72 % versus ≈ 61 % with surgery alone. [@5]

Platinums

• Cisplatin remains the standard platinum when combined with fluoropyrimidines; as a single agent it achieves a response rate of 10‑20 %. [@6]
• Oxaliplatin is preferred over cisplatin because of a more favorable toxicity profile and provides a modest overall‑survival gain of < 1 month compared with cisplatin‑based regimens. [@7]

Anthracyclines

• Epirubicin, incorporated in the ECF/ECX regimen, increased 5‑year survival from 23 % to 36 % in the MAGIC trial. [@8]
• Doxorubicin, formerly part of the FAM regimen, showed no significant survival advantage in later studies. [@6]

Taxanes

• Adding docetaxel to mono‑ or doublet chemotherapy yields a small overall‑survival benefit (≈ 1 month). [@1]
• Paclitaxel is active both as a single agent and in combination, notably in the RAINBOW regimen with ramucirumab. [@6]

Topoisomerase‑I Inhibitors

• Irinotecan extends overall survival by ≈ 1.6 months versus regimens without it and is better tolerated than platinum‑based therapy. [@6]
• Etoposide as monotherapy produces response rates of 10‑20 % but is limited in use. [@6]

3. Targeted and Immunologic Therapies

• Trastuzumab must be added to first‑line chemotherapy (platinum + fluoropyrimidine) for HER2‑positive advanced gastric adenocarcinoma. [@1]
• Nivolumab combined with fluoropyrimidine + oxaliplatin is indicated first‑line for advanced disease with PD‑L1 CPS ≥ 1 (Category 1 for CPS ≥ 5). [@1]
• Pembrolizumab combined with chemotherapy is approved first‑line for CPS ≥ 1 regardless of HER2 status. [@1]

4. Peri‑operative (Neoadjuvant/Adjuvant) Strategies

• The ECF/ECX regimen (3 pre‑op + 3 post‑op cycles) is the established standard in Europe/UK for resectable stage II‑III gastric cancer. [@9]
• The FLOT regimen (5‑FU + leucovorin + oxaliplatin + docetaxel) demonstrated superior median overall survival (50 months vs 35 months) and is now preferred when available. [@10]
• Cisplatin + 5‑FU (French FNCLCC/FFCD protocol) yields outcomes comparable to the MAGIC trial. [@4]

5. Adjuvant (Post‑operative) Therapy

• CAPOX (capecitabine + oxaliplatin) for 6‑8 cycles after D2 resection (stage III) provides 3‑year disease‑free survival of 74 % versus 59 % (CLASSIC trial). [@11]
• S‑1 for 12 months is an acceptable alternative in Asian patients after D2 resection, achieving 3‑year overall survival of 80 % versus 70 % with surgery alone. [@6]
• 5‑FU + leucovorin with concurrent radiotherapy (INT‑0116 protocol) is the U.S. standard for patients who did not receive neoadjuvant chemotherapy; however, 54 % of participants had suboptimal (D1) lymphadenectomy. [@8]

6. First‑line Therapy for Advanced/Metastatic Disease

HER2‑positive

• Preferred: fluoropyrimidine + oxaliplatin + trastuzumab ± pembrolizumab (if CPS ≥ 1). [@1]
• Alternative: fluoropyrimidine + cisplatin + trastuzumab ± pembrolizumab. [@1]

HER2‑negative

• Preferred: fluoropyrimidine + oxaliplatin + nivolumab (CPS ≥ 1; Category 1 for CPS ≥ 5). [@1]

• Alternative: fluoropyrimidine + oxaliplatin + pembrolizumab (CPS ≥ 1). [@1]

• Two‑drug platinum + fluoropyrimidine combinations are favored for lower toxicity; three‑drug regimens (DCF, mDCF) are reserved for patients with excellent performance status and high tumor burden. [@7]

7. Second‑line Therapy

• Monotherapy with a taxane (docetaxel or paclitaxel) or irinotecan is an accepted option after progression on first‑line therapy. [@1]

8. Biomarker Testing

• HER2 testing is mandatory in all cases of advanced gastric adenocarcinoma to determine eligibility for trastuzumab. [@1]
• PD‑L1 CPS assessment guides first‑line immunotherapy selection. [@1]

9. Clinical Impact and Safety Considerations

• Chemotherapy adds a median overall‑survival benefit of ≈ 6.7 months compared with best supportive care in advanced disease. [@6]
• Irinotecan is preferred as a second‑line option after platinum failure due to its tolerability. [@6]
• Oxaliplatin is favored over cisplatin because of reduced nephro‑ and ototoxicity. [@7]
• Capecitabine can replace 5‑FU to avoid central venous access without compromising efficacy. [@3]
• S‑1 remains investigational in Western populations and lacks validation outside Asia. [@5]

Peri‑operative and Adjuvant Treatment Recommendations for Resectable Gastric Cancer

1. Peri‑operative Chemotherapy (Neoadjuvant + Adjuvant)

• The NCCN guideline recommends peri‑operative chemotherapy (three pre‑operative cycles, surgery with D2 lymphadenectomy, then three post‑operative cycles) as the standard for resectable gastric cancer; the FLOT regimen is the preferred option when available, with ECF/ECX as an established alternative. 1
• The ECF/ECX regimen (epirubicin + cisplatin + continuous‑infusion 5‑FU or oral capecitabine) is administered as three pre‑operative cycles, surgery, and three post‑operative cycles. [2][3]4
• In the MAGIC phase‑III trial, peri‑operative ECF/ECX increased 5‑year overall survival from 23 % to 36 % compared with surgery alone. [2][3]4
• Capecitabine can replace continuous‑infusion 5‑FU without loss of efficacy, eliminating the need for a central venous catheter. [2][3]4
• A French regimen of cisplatin + 5‑FU (cisplatin 100 mg/m² day 1 + 5‑FU 800 mg/m² days 1‑5 every 28 days) produced outcomes comparable to the MAGIC trial. [2][3]4

2. Adjuvant Chemotherapy After D2 Lymphadenectomy (No Neoadjuvant Therapy)

• NCCN recommends postoperative chemotherapy alone after a D2 lymphadenectomy for stage III disease; this is considered a Category 1 recommendation. [5][6]1

3. Adjuvant Chemoradiotherapy After Sub‑optimal Lymphadenectomy (< D2)

• In the United States, the INT‑0116 protocol (5‑FU/leucovorin + concurrent radiotherapy 45 Gy/25 fractions, delivered during cycles 2‑3) is the standard adjuvant chemoradiotherapy for patients who did not receive neoadjuvant chemotherapy and had less than a D2 resection. [7][2][3][4]
• A critical observation from INT‑0116: 54 % of participants underwent less than a D1 lymphadenectomy, suggesting the chemoradiotherapy may be compensating for sub‑optimal surgery. [7][2][3][4]
• Retrospective analysis of the Dutch D1D2 trial showed that adjuvant chemoradiotherapy reduces local recurrence after a D1 resection but provides no additional benefit after a D2 resection. [2][3]4

4. First‑Line Systemic Therapy for Metastatic Disease

4.1 HER2‑positive adenocarcinoma

• Preferred regimen: fluoropyrimidine (5‑FU or capecitabine) + oxaliplatin + trastuzumab + pembrolizumab for tumors with CPS PD‑L1 ≥ 1. 1
• Alternative regimen: fluoropyrimidine + cisplatin + trastuzumab ± pembrolizumab (if CPS ≥ 1). 1
• NCCN mandates the addition of trastuzumab to first‑line chemotherapy for HER2‑positive metastatic gastric adenocarcinoma (Category 1). [5][6]1

4.2 HER2‑negative adenocarcinoma

• Preferred regimen: fluoropyrimidine + oxaliplatin + nivolumab for CPS PD‑L1 ≥ 1 (Category 1 for CPS ≥ 5). 1
• Alternative regimen: fluoropyrimidine + oxaliplatin + pembrolizumab for CPS ≥ 1. 1

4.3 General Principles for Advanced Disease

• Two‑drug cytotoxic regimens are preferred because of lower toxicity (Category 1). [5][6]1
• Three‑drug cytotoxic regimens should be reserved for patients with excellent performance status and the ability to undergo frequent toxicity monitoring. [5][6]1
• The ECF regimen remains one of the most active and well‑tolerated options for advanced disease. [7][8]
• Oxaliplatin is preferred over cisplatin due to a more favorable toxicity profile. 1
• Capecitabine and 5‑FU are interchangeable without compromising efficacy. [5][6]

5. Second‑Line Systemic Therapy

• After progression on first‑line therapy, monotherapy with a taxane (docetaxel or paclitaxel) or irinotecan is an accepted NCCN‑endorsed option (Category 1). 1

6. Biomarker Testing

• HER2 testing is mandatory in all cases of advanced gastric adenocarcinoma to determine eligibility for trastuzumab. 1
• Assessment of CPS PD‑L1 guides selection of first‑line immunotherapy. 1

7. Critical Surgical and Staging Recommendations

• Adequate lymph node assessment requires retrieval of at least 14 nodes (optimally ≥ 25) for accurate staging (Category 1). 7
• Laparoscopic staging should be performed before definitive surgery for potentially resectable stage IB‑III disease, as imaging alone misses a significant proportion of peritoneal metastases. 2
• Post‑operative chemotherapy carries a substantial toxicity burden; careful patient selection is required (Category 1). 7

Evidence‑Based Management of Stage IV Gastric Adenocarcinoma

Prognostic Determinants

• Performance status is the primary clinical factor guiding chemotherapy eligibility; patients with adequate functional status derive benefit from systemic therapy (NCCN recommendation) [9][10]

Mandatory Biomarker Assessment

• Microsatellite instability (MSI) / deficient mismatch repair (dMMR) testing must be performed in all patients to identify those who may benefit from immunotherapy (NCCN guideline) 11

First‑Line Systemic Therapy

HER2‑Positive Disease (≈10–15 % of cases)

• Adding trastuzumab to a platinum‑fluoropyrimidine doublet increases median overall survival from 11.1 months to 13.8 months (Category 1 evidence) 9
• The survival benefit of trastuzumab is greatest in tumors with IHC 3+ or IHC 2+/FISH‑positive status 9

HER2‑Negative, PD‑L1 CPS ≥ 1

• Fluoropyrimidine + oxaliplatin + nivolumab is the preferred regimen for patients with CPS ≥ 5 (NCCN Category 1) 11
• Fluoropyrimidine + oxaliplatin + pembrolizumab is an acceptable alternative 11

HER2‑Negative, PD‑L1‑Negative or Low CPS

• EOX (epirubicin + oxaliplatin + capecitabine) provides a median overall survival of ≈11.2 months, avoids the need for a central venous catheter, and reduces thromboembolic risk compared with ECF [9][10]
• ECX (epirubicin + cisplatin + capecitabine) is non‑inferior to ECF in the REAL‑2 trial [9][10]
• ECF (epirubicin + cisplatin + 5‑FU) remains an active and well‑tolerated doublet but requires central venous access [12][13][9][10]

Triplet Regimens (Highly Selected Patients)

• Docetaxel + cisplatin + 5‑FU (DCF) can add ~1 month of overall survival in patients with excellent performance status, but markedly increases febrile neutropenia risk [9][10]

Alternative Doublet Options

• Irinotecan + 5‑FU/leucovorin offers comparable activity to cisplatin‑based regimens with better tolerability [12][13]9
• Taxane‑based combinations (docetaxel or paclitaxel + platinum/fluoropyrimidine) are viable alternatives [9][10]

Chemotherapy Component Selection

• Capecitabine and 5‑FU are interchangeable without loss of efficacy [9][10]
• Capecitabine eliminates the need for a central line and lowers thromboembolic risk [9][10]
• Oxaliplatin is preferred over cisplatin because it provides equivalent efficacy with reduced nephro‑, oto‑, and gastrointestinal toxicity (Category 1) 9
• Adding epirubicin to a platinum‑fluoropyrimidine doublet yields a significant survival advantage (meta‑analysis) [9][10]
• In the peri‑operative setting, epirubicin‑containing ECF improved 5‑year survival from 23 % to 36.3 % (MAGIC trial) [12][13]

Second‑Line Therapy

• Weekly paclitaxel is the preferred monotherapy after first‑line progression [9][10]
• Docetaxel is an alternative second‑line agent [9][10]
• Irinotecan is preferred after platinum failure because of superior tolerability [9][10]
• Second‑line chemotherapy extends median overall survival to 8–9 months and improves quality of life versus best supportive care [9][10]
• Patients whose disease progresses >3 months after first‑line therapy may be re‑challenged with the same regimen 9

Critical Pitfalls to Avoid

• Do not administer chemotherapy to patients with poor performance status (ECOG ≥ 2) (NCCN recommendation) [9][10]
• Mandatory HER2 testing is required; omission denies patients a proven survival‑benefiting targeted therapy (NCCN) 11
• PD‑L1 CPS testing is essential for selecting immunotherapy‑containing regimens (NCCN) 11
• When oxaliplatin is available, avoid cisplatin because oxaliplatin offers equivalent efficacy with markedly better tolerability 9
• Chemotherapy should not be continued indefinitely; symptom‑driven follow‑up is recommended (NCCN) [12][13]
• Radiologic assessment should be performed at regular intervals to guide continuation or modification of therapy 9

Special Considerations

• Hypofractionated palliative radiotherapy effectively controls bleeding, obstruction, or pain from locally advanced disease 9
• Palliative gastrectomy may be considered in highly selected patients who achieve an excellent response to systemic therapy [9][10]
• Routine resection of the primary tumor is not recommended in the palliative setting 9
• Enrollment in clinical trials should be offered whenever possible, especially in the second‑line setting where no standard regimen exists [12][13][9][10]